- Home
- BOLD vs TRT Comparison
BOLD vs TRT Comparison
Compare BOLD & TRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- TRT
- Stock Information
- Founded
- BOLD 2018
- TRT 1958
- Country
- BOLD United States
- TRT United States
- Employees
- BOLD N/A
- TRT N/A
- Industry
- BOLD
- TRT Industrial Machinery/Components
- Sector
- BOLD
- TRT Technology
- Exchange
- BOLD Nasdaq
- TRT Nasdaq
- Market Cap
- BOLD 24.4M
- TRT 22.7M
- IPO Year
- BOLD 2024
- TRT N/A
- Fundamental
- Price
- BOLD $1.15
- TRT $5.25
- Analyst Decision
- BOLD Buy
- TRT
- Analyst Count
- BOLD 4
- TRT 0
- Target Price
- BOLD $4.00
- TRT N/A
- AVG Volume (30 Days)
- BOLD 79.9K
- TRT 2.6K
- Earning Date
- BOLD 11-06-2025
- TRT 11-11-2025
- Dividend Yield
- BOLD N/A
- TRT N/A
- EPS Growth
- BOLD N/A
- TRT N/A
- EPS
- BOLD N/A
- TRT 0.00
- Revenue
- BOLD N/A
- TRT $35,548,000.00
- Revenue This Year
- BOLD N/A
- TRT N/A
- Revenue Next Year
- BOLD N/A
- TRT N/A
- P/E Ratio
- BOLD N/A
- TRT $1,191.70
- Revenue Growth
- BOLD N/A
- TRT N/A
- 52 Week Low
- BOLD $1.00
- TRT $4.62
- 52 Week High
- BOLD $4.72
- TRT $7.88
- Technical
- Relative Strength Index (RSI)
- BOLD 49.88
- TRT 43.61
- Support Level
- BOLD $1.13
- TRT $5.12
- Resistance Level
- BOLD $1.16
- TRT $5.50
- Average True Range (ATR)
- BOLD 0.04
- TRT 0.09
- MACD
- BOLD 0.00
- TRT -0.01
- Stochastic Oscillator
- BOLD 62.50
- TRT 34.21
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About TRT Trio-Tech International
Trio-Tech International is a provider of third-party semiconductor testing and burn-in services through its laboratories in Southeast Asia. The company operates in four segments namely Manufacturing, Testing services, Distribution, and Real Estate. Its Manufacturing segment manufactures both front-end and back-end semiconductor test equipment and related peripherals. The Testing Services segment renders services to the manufacturer and purchaser of semiconductors and other entities. Its Distribution segment is involved in the distribution of its products. The company's Real Estate segment consists of investment in real estate. Its geographical area of operations includes the United States, Singapore, Malaysia, Thailand, and China. It derives maximum revenue from Testing services Segment.